{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:28:15Z","timestamp":1778797695497,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,3,23]],"date-time":"2027-03-23T00:00:00Z","timestamp":1805760000000},"content-version":"am","delay-in-days":265,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R01 EY029795"],"award-info":[{"award-number":["R01 EY029795"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019125","name":"National Institute of Pharmaceutical Education and Research, Ahmedabad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019125","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","award":["09\/0727"],"award-info":[{"award-number":["09\/0727"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","award":["12056)\/2021-EMR-1"],"award-info":[{"award-number":["12056)\/2021-EMR-1"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","award":["09\/0727(12056)\/2021-EMR-1"],"award-info":[{"award-number":["09\/0727(12056)\/2021-EMR-1"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["BT\/PR62235\/2025"],"award-info":[{"award-number":["BT\/PR62235\/2025"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["BT \/PR42965\/PBD\/26\/821\/2021"],"award-info":[{"award-number":["BT \/PR42965\/PBD\/26\/821\/2021"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Protein Expression and Purification"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.pep.2026.106922","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T15:56:36Z","timestamp":1774108596000},"page":"106922","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Development and partial characterization of fused human endostatin"],"prefix":"10.1016","volume":"241","author":[{"given":"J.","family":"Anakha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yenisetti Rajendra","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Chakka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shyam S.","family":"Chaurasia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhay H.","family":"Pande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pep.2026.106922_bib1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12032-023-02245-w","article-title":"Recombinant human endostatin as a potential anti-angiogenic agent: therapeutic perspective and current status","volume":"41","author":"Anakha","year":"2023","journal-title":"Medical oncology (Northwood, London, England)"},{"issue":"1","key":"10.1016\/j.pep.2026.106922_bib2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40364-025-00779-x","article-title":"Decoding tumor angiogenesis: pathways, mechanisms, and future directions in anti-cancer strategies","volume":"13","author":"Liu","year":"2025","journal-title":"Biomark. Res."},{"issue":"3","key":"10.1016\/j.pep.2026.106922_bib3","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10456-023-09876-7","article-title":"Pathological angiogenesis: mechanisms and therapeutic strategies","volume":"26","author":"Dudley","year":"2023","journal-title":"Angiogenesis"},{"issue":"6","key":"10.1016\/j.pep.2026.106922_bib4","doi-asserted-by":"crossref","first-page":"918","DOI":"10.4103\/2230-8210.102992","article-title":"Aberrant angiogenesis: the gateway to diabetic complications","volume":"16","author":"Kota","year":"2012","journal-title":"Indian journal of endocrinology and metabolism"},{"issue":"1","key":"10.1016\/j.pep.2026.106922_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12272-020-01287-2","article-title":"Pathological angiogenesis and inflammation in tissues","volume":"44","author":"Jeong","year":"2021","journal-title":"Arch Pharm. Res. (Seoul)"},{"key":"10.1016\/j.pep.2026.106922_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2024.107459","article-title":"Endostatin in disease modulation: from cancer to beyond","volume":"158","author":"Anakha","year":"2025","journal-title":"Vasc. Pharmacol."},{"issue":"11","key":"10.1016\/j.pep.2026.106922_bib7","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1136\/bjophthalmol-2013-303513","article-title":"Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration","volume":"97","author":"Krebs","year":"2013","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.pep.2026.106922_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100906","article-title":"Incomplete response to Anti-VEGF therapy in neovascular AMD: exploring disease mechanisms and therapeutic opportunities","volume":"82","author":"Mettu","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.pep.2026.106922_bib9","article-title":"Endostatin-based anti-angiogenic therapy and immune modulation: mechanisms and synergistic potential in cancer treatment","volume":"16","author":"Sun","year":"2025","journal-title":"Front. Immunol."},{"issue":"14","key":"10.1016\/j.pep.2026.106922_bib10","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/rcm.367","article-title":"Determination of the disulfide bond pattern of the endogenous and recombinant angiogenesis inhibitor endostatin by mass spectrometry","volume":"15","author":"John","year":"2001","journal-title":"Rapid Commun. Mass Spectrom. : RCM (Rapid Commun. Mass Spectrom.)"},{"issue":"16","key":"10.1016\/j.pep.2026.106922_bib11","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1016\/j.febslet.2007.05.058","article-title":"Contributions of Zn(II)-binding to the structural stability of endostatin","volume":"581","author":"Han","year":"2007","journal-title":"FEBS Lett."},{"issue":"12","key":"10.1016\/j.pep.2026.106922_bib12","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.bbagen.2015.09.007","article-title":"Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications","volume":"1850","author":"Walia","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"issue":"5","key":"10.1016\/j.pep.2026.106922_bib13","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s10637-023-01387-y","article-title":"Development and characterization of fused human arginase I for cancer therapy","volume":"41","author":"Jawalekar","year":"2023","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.pep.2026.106922_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.enzmictec.2023.110209","article-title":"Fused human paraoxonase 1 as a prophylactic agent against organophosphate poisoning","volume":"165","author":"Dobariya","year":"2023","journal-title":"Enzym. Microb. Technol."},{"issue":"4","key":"10.1016\/j.pep.2026.106922_bib15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40259-015-0133-6","article-title":"Fusion proteins for half-life extension of biologics as a strategy to make biobetters","volume":"29","author":"Strohl","year":"2015","journal-title":"BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy"},{"issue":"1","key":"10.1016\/j.pep.2026.106922_bib16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/14712598.2024.2436094","article-title":"Strategies for extending the half-life of biotherapeutics: successes and complications","volume":"25","author":"Binder","year":"2025","journal-title":"Expet Opin. Biol. Ther."},{"issue":"1","key":"10.1016\/j.pep.2026.106922_bib17","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/s42003-025-08249-8","article-title":"Enhanced plasma half-life and efficacy of engineered human albumin-fused GLP-1 despite enzymatic cleavage of its C-terminal end","volume":"8","author":"Nilsen","year":"2025","journal-title":"Commun. Biol."},{"issue":"10","key":"10.1016\/j.pep.2026.106922_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103738","article-title":"Human serum albumin binders: a piggyback ride for long-acting therapeutics","volume":"28","author":"Ullah","year":"2023","journal-title":"Drug Discov. Today"},{"issue":"11","key":"10.1016\/j.pep.2026.106922_bib19","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1210\/clinem\/dgaa538","article-title":"MicroRNA-15b targets VEGF and inhibits angiogenesis in proliferative diabetic retinopathy","volume":"105","author":"Yang","year":"2020","journal-title":"J. Clin. Endocrinol. Metabol."},{"issue":"11","key":"10.1016\/j.pep.2026.106922_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112448","article-title":"Anti-angiogenic effects of a mutant endostatin: a new prospect for treating retinal and choroidal neovascularization","volume":"9","author":"Bai","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.pep.2026.106922_bib21","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1124\/jpet.122.001529","article-title":"Siponimod as a novel inhibitor of retinal angiogenesis: in vitro and in vivo evidence of therapeutic efficacy","volume":"386","author":"Alshaikh","year":"2023","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"1","key":"10.1016\/j.pep.2026.106922_bib22","first-page":"53","article-title":"Chloroquine increases the anti-cancer activity of epirubicin in A549 lung cancer cells","volume":"20","author":"Liang","year":"2020","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.pep.2026.106922_bib23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bbrc.2007.06.155","article-title":"Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR\/Flk-1 of endothelial cells","volume":"361","author":"Ling","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/j.pep.2026.106922_bib24","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10637-024-01466-8","article-title":"Broad-spectrum anti-cancer activity of fused human arginase variants","volume":"42","author":"Prasad","year":"2024","journal-title":"Invest. N. Drugs"},{"issue":"9","key":"10.1016\/j.pep.2026.106922_bib25","doi-asserted-by":"crossref","first-page":"5867","DOI":"10.1002\/jcp.29583","article-title":"Pichia pastoris: a highly successful expression system for optimal synthesis of heterologous proteins","volume":"235","author":"Karbalaei","year":"2020","journal-title":"J. Cell. Physiol."},{"issue":"4","key":"10.1016\/j.pep.2026.106922_bib26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/emm.1999.32","article-title":"Purification and characterization of recombinant murine endostatin in E. coli","volume":"31","author":"You","year":"1999","journal-title":"Exp. Mol. Med."},{"issue":"10","key":"10.1016\/j.pep.2026.106922_bib27","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1089\/104303403766682250","article-title":"Endostatin exhibits a direct antitumor effect in addition to its antiangiogenic activity in colon cancer cells","volume":"14","author":"Dkhissi","year":"2003","journal-title":"Hum. Gene Ther."}],"container-title":["Protein Expression and Purification"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1046592826000458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1046592826000458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T21:52:25Z","timestamp":1778795545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1046592826000458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":27,"alternative-id":["S1046592826000458"],"URL":"https:\/\/doi.org\/10.1016\/j.pep.2026.106922","relation":{},"ISSN":["1046-5928"],"issn-type":[{"value":"1046-5928","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and partial characterization of fused human endostatin","name":"articletitle","label":"Article Title"},{"value":"Protein Expression and Purification","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pep.2026.106922","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106922"}}